Interleukin-8 in breast cancer progression

Journal of Interferon and Cytokine Research

Volumn 33, Issue 10, 2013, Pages 563-570

  Todorović Raković, Nataša ^a   Milovanović, Jelena ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; DOCETAXEL; ESTROGEN RECEPTOR; GEFITINIB; INTERLEUKIN 8;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CYTOKINE PRODUCTION; HUMAN; METASTASIS; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-8; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84885659220     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0023     Document Type: Review

References (77)

1. Aceto N, Duss S, Macdonald G, Meyer DS, Roloff TC, Hynes NE, et al. 2012. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res 14:R131.
2. Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A. 2005. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 217:73-86. (Pubitemid 39642868)
3. Bendrik C, Dabrosin C. 2009. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 182:371-378.
4. Benoy IH, Salgado R, Van Dam P, Eboers K, Van Marck E, Scharpé S, et al. 2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10:7157-7162. (Pubitemid 39487700)
5. Brat DJ, Bellail AC, Van Meir EG. 2005. The role of Interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neurooncology 7:122-133. (Pubitemid 40590513)
6. Brew R, Erikson JS, West DC, et al. 2000. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12:78-85. (Pubitemid 30042685)
7. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiè re F, Laune D, et al. 2007. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9:R15.
8. Chelouche-Lev D, Miller CP, Tellez C, Ruiz M, Bar-Eli M, Price JE. 2004. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 40:2509-2518. (Pubitemid 39424968)
9. Chen Y, Shi M, Yu G-Z, Qin X-R, Jin G, Chen P, et al. 2012. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 18:1123-1129.
10. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. 2011. Microarrays in the 2010s: the contribution of microarraybased gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13:212.
11. De Larco JE, Wuertz BR, Furcht LT. 2004. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895-4900. (Pubitemid 39099762)
12. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. 2001. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158:639-646. (Pubitemid 32158624)
13. De Larco JE, Wuertz BR, Yee D, Rickert BL, Furcht LT. 2003. Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc Natl Acad Sci USA100:13988-13993. (Pubitemid 37499178)
14. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. 1999. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445-3453
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784.
16. Ewington L, Taylor A, Sriraksa R, Horimoto Y, Lam EW, El-Bahrawy MA. 2012. The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma. Cytokine 59:417-422.
17. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. 2011. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71:5296-5306.
18. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, et al. 2003. IL-8 expression and its possible relationship with estrogen-receptor- negative status of breast cancer cells. Oncogene 22:256-265. (Pubitemid 36174182)
19. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, et al. 2004. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23:6105-6114. (Pubitemid 39178863)
20. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. 2010. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485-497.
21. Gomperts BN, Strieter RM. 2006. Chemokine-directed metastasis. Contrib Microbiol 13:170-190.
22. Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A. 2011. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia 13:230-243.
23. Hayes E, Nicholson RI, Hiscox S. 2011. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 16:838-848.
24. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. 1991. Structure and functional expression of a human interleukin-8 receptor. Science 253:1278-1280. (Pubitemid 21917277)
25. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD. 2000a. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119. (Pubitemid 30305111)
26. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP. 2000b. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60:2290-2299. (Pubitemid 30225196)
27. Keeley EC, Mehrad B, Strieter RM. 2010. CXC chemokines in cancer angiogenesis and metastases; Adv Cancer Res 106:91-111.
28. Knall C, Young S, Nick JA, Buhl AM, Worthen GS, Johnson GL. 1996. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J Biol Chem 271:2832-2838. (Pubitemid 26047904)
29. Kotyza J. 2012. Interleukin-8 (CXCL8) in tumor associated nonvascular extracellular fluids: its diagnostic and prognostic values. A review. Int J Biol Markers 27:e169-e178.
30. Lagiou P, Trichopoulos D. 2011. Inflammatory biomarkers and risk of lung cancer Pagona lagiou and dimitrios trichopoulos J Natl Cancer Inst 103:1073-1075.
31. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, et al. 2012. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106:1833-1841.
32. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170:3369-3376. (Pubitemid 36302216)
33. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. 2005. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8:63-71. (Pubitemid 41223840)
34. Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, et al. 2012. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis 33:1302-1309.
35. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, et al. 2004. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109:507-515. (Pubitemid 38339640)
36. Lin Y, Wang SM, Huang RP. 2005. Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor. Zhonghua Yi Xue Za Zhi 85:1419-1423. (Pubitemid 40852102)
37. Martin D, Galisteo R, Gutkind JS. 2009. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1complex. J Biol Chem 284:6038-6042.
38. Miller LJ, Kurtzman SH, Wang Y, et al. 1998. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 18:77-81. (Pubitemid 28174688)
39. Miyamoto M, Shimizu Y, Okada K, et al. 1998. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother 47:47-57. (Pubitemid 28430530)
40. Mohamed MM. 2012. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway. Cell Commun Signal 10:3.
41. Nastase A, Pâ slaru L, Niculescu AM, Ionescu M, Dumitrasxcu T, Herlea V, et al. 2011. Prognostic and predictive potential molecular biomarkers in colon cancer. Chirurgia (Bucur) 106:177-185.
42. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. 2011. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 128:2038-2049.
43. Opdenakker G, Van Damme J. 2004. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 48:519-527. (Pubitemid 39360402)
44. Osborne CK. 1998. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51:227-238. (Pubitemid 29054556)
45. Papaxoinis G, Pectasides DG, Korantzis I, Koutras A, Kosmidis PA, Linardou H, et al. 2010. Plasma angiogenic markers in patients with metastatic breast cancer treated with weekly docetaxel. J Clin Oncol 28:e21004.
46. Parise CA, Bauer KR, Brown MM, Caggiano V. 2009. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.Breast J 15:593-602.
47. Patel PS, Varney ML, Dave BJ, Singh RK. 2002. Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. J Interferon Cytokine Res 22:427-435. (Pubitemid 34579545)
48. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. 2001. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-99. (Pubitemid 32269934)
49. Prat A, Baselga J. 2008. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531-542.
50. Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. 2007. Serum cytokine levels of interleukin-1beta,-6,-8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol 100:387-391. (Pubitemid 46776388)
51. Richmond A, Yang J, Su Y. 2009. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175-186.
52. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, et al. 2011. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97.
53. Russell K, Hung M-C. 1992. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624-6629.
54. Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB. 2010. Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. LabMedicine 41:364-372.
55. Shahzad A, Knapp M, Lang I, Kö hler G. 2010. Interleukin 8 (IL-8)-a universal biomarker? Int Arch Med 3:11.
56. Sharma B, Singh RK. 2011. Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinogen 10:36.
57. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. 2006. CD44 +/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59.
58. Singh B, Berry JA, Shoher A, Lucci A. 2006. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 131:267-275.
59. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, Howell SJ, Clarke RB. 2013. Targetting CXCR significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and-independent mechanisms. Clin Cancer Res 19:643-656.
60. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. 1994. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54:3242-3247. (Pubitemid 24208936)
61. Singh RK, Lokeshwar BL. 2009. Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8:57.
62. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al. 2007. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6:1973-1982. (Pubitemid 47052487)
63. Singh S, Singh AP, Sharma B, Owen LB, Singh RK. 2010. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 6:111-116.
64. Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN, et al. 2010. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 10:283.
65. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, et al. 2012. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 12:12.
66. Vandercappellen J, Van Damme J, Struyf S. 2008. The role of CXC chemokines and their receptors in cancer. Cancer Lett 267:226-244.
67. Vazquez-Martin A, Colomer R, Menendez JA. 2007. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 43:1117-1124. (Pubitemid 46590736)
68. Venkatakrishnan G, Salgia R, Groopman JE. 2000. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 275:6868-6875. (Pubitemid 30146227)
69. Wang Y, Guo XQ, Niu XL, Wu J, Zhu YQ, Mao LQ. 2010. Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 1:21-24.
70. Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, et al. 2005. Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2:365-272.
71. Waugh DJJ, Wilson C. 2008. The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735.
72. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr., Le XF. 2006. HER2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25:6986-6996. (Pubitemid 44684839)
73. Yang J, Wang Y, Gao Y, Shao J, Zhang XJ, Yao Z. 2009. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 46:382-391.
74. Yang W, Li-Pai C, Huang R, Huang R-P. 2005. Inhibition of IL-6 and IL-8 enhances chemosensitization in multidrug resistant human breast cancer cells. Proc Amer Assoc Cancer Res 46:Abstract No. 5079.
75. Yao C, Lin Y, Ye CS, Bi J, Zhu YF, Wang SM. 2007. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl) 120:1766-1772. (Pubitemid 350111080)
76. Yuan A, Chen JJ, Yao PL, Yang PC. 2005. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10:853-865.
77. Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, et al. 2012. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem 114:571-576.